2NAJEAN Y, DREACH C, RAIN J D: The very long term course of polycythemia: a complenent to the previously published date of PVSG[J]. Br J Haematol,1994,86:233.
3CASTELLO G, LERZA R, CERRUTTI D, et al. The in vivtro and in vivo effect of recombinant interferon alpha-2 α on circulating heamatopoietic progenitor cells in polycythemia vera[J]. Br J Haematol, 1994, 87: 621-623.
4Ferster A, Tahriri P, Vermylen C, et al. Five years of experience with hydroxyurea in children and young adults with disease [J]. Blood, 2001,97(11):6628-3632
5Steinberg M H, Barton F, Castro O,et al. Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treatment [J].JAMA ,2003,289 (13) : 1645-1651
6Hoppe C, Vichinsky E, Quirolo K,et al. Use of hydroxyurea in children ages 2 to 5 years with sickle cell disease[J]. J Pediatr Hematol Oncol,2000,22(4) :330-334
7Arruda VR, Lima CS, Saad St, et al. Successful use of hydroxyurea in beta-thalassemia major[J]. N Engl J Med, 1997,336(13) :964
8Kumar B ,Saraswat A , Kaur I. Rediscovering hydroxyurea: its role in recalcitrant psoriasis[J] . Invt J Dermatol, 2001,40(8) :530-534
9Fruchtman SM, Mack K, Kaplan ME, et al. From efficacy to safty ,apolycythemia vera study group report on hydroxyurea in patients with polycythemia vera[J].Semin Hematol, 1997,34:17-21
10Piccinini G, Foli A, Comolli G, et al. Complementary antiviral efficacy of hydroxyurea and protease inhibitors in human immunodeficiency virus - infected dendritic cells and lymphocytes [J]. J Virol. 2002,76 (5) :2274-2278
